APIM Therapeutics annouced today that since the proposed merger transaction with Nordic Nanovector ASA, a listed Norwegian biotechnology company (OSE: NANOV), did not obtain sufficient majority of votes at the Extraordinary General Meeting of the shareholders of Nordic Nanovector held on December 1st, 2022, the planned all-stock transaction between the companies was thereby cancelled. APIM Therapeutics will continue advancing its lead candidate ATX-101 in clinical trials, expecting to meet significant milestones in the period of 2023 & 2024.
